Ouronyx Blog
Beyond Volume: How Injectable Treatments Are Evolving
Part of that shift comes from a better understanding of facial ageing itself. The face does not change through volume loss alone. Skin quality, fat distribution, structural support and the deeper anatomy of the face all evolve over time, which means simply replacing volume is not always the most appropriate answer. Facial ageing is a multidimensional process, and treatment increasingly needs to reflect that complexity.
This is also changing what many clients expect from injectable treatments. Rather than asking how much volume can be restored, the conversation is increasingly about how the face can be supported while preserving its natural proportions.
Hybrid injectables have a role within that evolution. By combining different mechanisms within one treatment, they can offer an alternative to purely volumising approaches. HArmonyCa, for example, combines Hyaluronic Acid (HA), which provides immediate structural support, with Calcium Hydroxyapatite (CaHA), which is associated with progressive collagen stimulation over time. Clinical studies have demonstrated changes in facial support, collagen-related tissue properties and skin quality following treatment.
At Ouronyx, however, the interest is not in using a newer or more complex injectable simply because it exists. The value of any product depends on knowing when it is appropriate, what it can realistically achieve and when another approach would serve the face better. What makes HArmonyCa particularly interesting is not simply how it works, but when a doctor decides to use it.
Our London doctors have been using HArmonyCa for the past few years and have seen high levels of satisfaction among appropriately selected clients. Over that time, it has become one of several options available when the concern is less about creating fullness and more about restoring support while also encouraging progressive improvement in tissue quality.
That experience has also reinforced an important principle: the product should never determine the treatment plan. Two clients may both notice softer contours or reduced definition, yet the anatomical reason behind that change can be very different. One may benefit from a hybrid injectable, another from a different form of structural support, skin treatment or biostimulation, while someone else may not need injectable treatment at all. The decision comes from the assessment, not from the syringe.
That is also why the recent introduction of HArmonyCa in Dubai is interesting to us. It is not a completely new treatment for Ouronyx. Rather, it allows us to bring several years of clinical experience from Europe into a market where the product itself has only recently become available.
Dr Thivos Sokratous and Dr Karim Sayed know very well how HArmonyCa behaves, where it can be useful and, equally importantly, where its limitations lie. That familiarity allows the conversation in Dubai to begin from experience rather than novelty.
More broadly, hybrid injectables reflect where aesthetic medicine continues to move: away from thinking exclusively in terms of filling individual areas and towards combining structural support, tissue quality and longer-term regeneration more intelligently.
At Ouronyx, that does not mean replacing one treatment trend with another. It means having a wider range of tools available, and enough clinical judgement to know which of them deserves a place in an individual treatment plan.
Book a Consultation
If you’re considering injectable treatment but are unsure which approach is right for your face, talk to our doctors in London or Dubai about the options available to you.